HIV Infections Clinical Trial
Official title:
The Lotto to Link Study: A Prospective, Interventional, Randomized Study of Conditional Incentives to Engage HIV-positive Men in HIV Care in KwaZulu-Natal, South Africa
In this study the investigators will adapt and strengthen, test effectiveness, and explore implementation of conditional lottery incentive linkage strategies to engage men in HIV care and ART in KwaZulu-Natal, South Africa.
Of the 2.6 million South Africans on antiretroviral therapy (ART)1 only a third are men,
despite men making up 45% of HIV-positive persons.2 HIV-positive men are underrepresented
throughout the HIV prevention and care continuum, being less likely to test, link to care,
initiate ART, and more likely to be lost to follow-up. Few strategies have focused on men,
and when they have they have not been successful. Even with community-based HIV testing,
referral, text message reminders, and lay-counselor support (an optimized testing and linkage
to care package), doctors are only able to achieve 60% linkage to HIV care and ART among men.
HIV-positive men who are not in care are at risk for HIV-associated morbidity and mortality,
and their HIV-negative partners are at risk of HIV acquisition. Innovative strategies are
needed to motivate HIV-positive men to engage in care, and specifically to initiate and
adhere to ART.
Introducing a gamble, the chance of winning a lottery, into linkage to HIV care interventions
could make engagement in care more attractive to men. Men are often risk-takers and linking
to care successfully is a gamble: start ART vs. risk no ART. A lottery incentive strategy has
been successfully used to increase uptake of HIV prevention; in one recent example, lottery
incentives, conditioned on being STI (sexually transmitted infection) negative, decreased HIV
incidence by 60% among 'risk-loving' individuals in Lesotho, demonstrating one of the largest
effects to date of a behavioral intervention for HIV prevention. Given this prevention
success, the investigators hypothesize that lottery incentives have the potential to overcome
both structural and behavioral factors for linking HIV positive men to care, addressing
logistical challenges and risk preferences specific to men. For scale-up and implementation,
the investigators need to sculpt the content of lottery incentive strategies as well as the
approach to identify men not in care for whom lottery incentives are likely to work.
In this study the investigators will adapt and strengthen, test effectiveness, and explore
implementation of conditional lottery incentive linkage strategies to engage men in HIV care
and ART in KwaZulu-Natal, South Africa (the Lotto to Link Study). With the investigators
experienced, multi-disciplinary team, the investigators have drawn on their previous
successful community-based counseling and testing and linkage to prevention and care work to
strengthen linkage strategies for HIV-positive ART eligible men who are not in care.
The investigators will do 1) qualitative interviews to inform the study design, 2) conduct an
individual randomized study of conditional lottery incentives compared to an optimized
linkage package for HIV-positive men, and 3) finally, estimate the costs associated with
conditional incentives and retention in care.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |